NCT03837964已完成1 期
Relative Bioavailability of BI 1291583 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Area under the concentration-time curve of BI 1291583 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
研究概览
简要总结
To assess the effect of food on the pharmacokinetics of an oral tablet formulation of BI 1291583, by investigating the relative bioavailability following single dose administration under fed and fasted conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests
- •Age of 18 to 45 years (inclusive)
- •Body mass index (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
- •Signed and dated written informed consent prior to admission to the study, in accordance with Good clinical practice (GCP) and local legislation
排除标准
- •Any finding in the medical examination (including Blood Pressure (BP), Pulse Rate (PR), or Electrocardiogram (ECG)) deviating from normal and assessed as clinically relevant by the investigator
- •Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm
- •Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
- •Any evidence of a concomitant disease assessed as clinically relevant by the investigator
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders
- •Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
- •Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
- •History of relevant orthostatic hypotension, fainting spells, or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients)
- •Use of drugs within 30 days of planned administration of trial medication that might reasonably influence the results of the trial (including drugs that cause QT/QTc interval prolongation)
- •Intake of an investigational drug in another clinical trial within 60 days of planned administration of investigational drug in the current trial, or concurrent participation in another clinical trial in which investigational drug is administered
- •Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
- •Inability to refrain from smoking on specified trial days
- •Alcohol abuse (consumption of more than 30 g per day)
- •Drug abuse or positive drug screening
- •Blood donation of more than 100 mL within 30 days of planned administration of trial medication or intended blood donation during the trial
- •Intention to perform excessive physical activities within one week prior to the administration of trial medication or during the trial
- •Inability to comply with the dietary regimen of the trial site
- •A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are greater than 450 ms, if confirmed by a second Electrocardiogram (ECG) recording) or any other relevant Electrocardiogram (ECG) finding at screening
- •A history of additional risk factors for Torsade de Pointes (such as heart failure, hypokalaemia, or family history of Long QT Syndrome)
- •Subject is assessed as unsuitable for inclusion by the investigator, for instance, because the subject is not considered able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
研究组 & 干预措施
Treatment T
Experimental
Fed
干预措施: BI 1291583 (Drug)
Treatment R
Experimental
Fasted
干预措施: BI 1291583 (Drug)
结局指标
主要结局
Area under the concentration-time curve of BI 1291583 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
时间窗: Within 3 hours (h) before and 0.5, 1, 2, 4, 5, 6, 7, 8, 10, 12, 14, 24, 34, 48, 72, 96, 120, 168, 216, 264 hours after drug administration
Area under the concentration-time curve of BI 1291583 in plasma over the time interval from 0 to the last quantifiable data point.
Maximum measured concentration of BI 1291583 in plasma (Cmax)
时间窗: Within 3 hours (h) before and 0.5, 1, 2, 4, 5, 6, 7, 8, 10, 12, 14, 24, 34, 48, 72, 96, 120, 168, 216, 264 hours after drug administration
Maximum measured concentration of BI 1291583 in plasma
次要结局
- Area under the concentration-time curve of BI 1291583 in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)(Within 3 hours (h) before and 0.5, 1, 2, 4, 5, 6, 7, 8, 10, 12, 14, 24, 34, 48, 72, 96, 120, 168, 216, 264 hours after drug administration)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Test How Food Influences the Amount of BI 1323495 in the Blood of Healthy MenHealthyNCT03802331Boehringer Ingelheim12
已完成
1 期
Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female SubjectsHealthyNCT02183493Boehringer Ingelheim32
已完成
1 期
Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male SubjectsHealthyNCT03302078Boehringer Ingelheim12
已完成
1 期
Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male VolunteersHealthyNCT02183389Boehringer Ingelheim18
已完成
1 期
A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1291583 in the BloodHealthyNCT03890887Boehringer Ingelheim14